None

IPO: Aratana in $57.5 million financing

Aratana Therapeutics filed a $57.5 million IPO. Stifel and Lazard Capital Markets are leading the offering with help from William Blair, JMP Securities and Craig-Hallum Capital Group. Aratana Therapeu...

Aratana Closes $12 Million Series C Financing to Fund Pipeline Expansion

KANSAS CITY, Kan. and BOSTON, Jan. 31, 2013 /PRNewswire/ -- Aratana Therapeutics, a biopharmaceutical company developing innovative medicines for cats and dogs (companion animals),...

Aratana to Participate in Leerink Swann's November Management Access Days

KANSAS CITY, Kan. and NEW YORK, Nov. 12, 2012 /PRNewswire/ -- Aratana Therapeutics, a biopharmaceutical company developing innovative medicines for cats and dogs (companion animals), tod...

Aratana to Present at Bank of America Merrill Lynch Animal Health Summit

KANSAS CITY, Kan., Dec. 7, 2012 /PRNewswire/ -- Aratana Therapeutics, a biopharmaceutical company developing innovative medicines for cats and dogs (companion animals), today announced that it will pa...

RaQualia looks to progress lead EP4 inhibitor on back of Aratana deal

Pfizer Japan spin-out RaQualia Pharma expects a new active pharmaceutical ingredient (API) development agreement with the private US firm Aratana Therapeutics to help progress the development of one...

Tetraphase, Aratana Make IPO Announcements

BRIEF: Tetraphase, Aratana Make IPO Announcements [Boston Herald] From Boston Herald (MA) (March 21, 2013) March 20--Tetraphase Pharmaceuticals Inc. today announced the pricing of its initial public o...

King: Hamburg's continued role as FDA chief is good for drugmakers

The pharmaceutical and biotech industry will benefit from the presumed continuation of Dr.  -More- Aratana Eyes Animal Markets For Human Drug Candidates Just like their human owners, dogs an...

Pacira licenses Exparel for veterinary uses

Pacira Pharmaceuticals Inc. said Thursday that Aratana Therapeutics will develop a version of its surgical pain drug Exparel for use in veterinary procedures.The Food and Drug Administration approved...

None